This presentation discusses the drug Linagliptin. It works by selectively inhibiting the DPP-4 enzyme, which helps increase levels of incretin hormones GLP-1 and GIP. This improves glucose regulation by increasing insulin secretion and lowering glucagon secretion in response to blood glucose levels. Linagliptin is indicated for use as both monotherapy and combination therapy with other drugs like metformin or sulfonylureas to control blood sugar levels in type 2 diabetes. The recommended dosage is 5mg once daily, with or without food. The drug offers effective control of A1C with a low risk of hypoglycemia and no weight gain. It is targeted towards several types of doctors including diabetologists and endocr

1. PRESENTATION
ON
Linagliptin
Prepared by:
Biplob Kumar Sarker
B. Pharm, M. Pharm

2. MODE OF ACTION
Linagliptin is a selective inhibitor of DPP-4
(Dipeptidyl Peptidase-4), an enzyme that
degrades the incretin hormones glucagon-
like peptide-1 (GLP-1) and glucose-
dependent insulinotropic polypeptide (GIP).
Lintin (Linagliptin) increases the
concentrations of active incretin hormones,
glucose-dependent insulin secretion and
lowers glucagon secretion, thus resulting in
better regulation of glucose haemostasis.

3. MODE OF ACTION…

4. INDICATION
 Monotherapy
Lintin (Linagliptin) tablet is indicated as an adjunct to
diet and exercise to improve glycemic control in
adults with type 2 diabetes mellitus.
 Combination Therapy
Lintin (Linagliptin) tablet can be administered as a
combination with metformin when diet and exercise
plus metformin alone do not provide adequate
glycemic control or in combination with a
sulphonylurea and metformin when diet and exercise
plus dual therapy do not provide adequate glycemic
control.

5. DOSAGE AND ADMINISTRATION …
 Recommended Dosing:
The recommended dose is 5 mg once daily. Lintin
(Linagliptin) tablets can be taken with or without food at
any time of the day. If a dose is missed, it should be taken
as soon as possible but a double dose should not be taken
on the same day.
 Concomitant Use:
When Linagliptin is used in combination with an insulin
secretagogue e.g., sulfonylurea or with insulin, a lower
dose of the insulin secretagogue or insulin may be
required to reduce the risk of hypoglycemia. If used with
metformin, the dose of metformin should be maintained.

6. KEY SELLING POINTS…
 Effectively Reduces HBA1C level as Monotherapy
and as add-on therapy to Metformin, Metformin+SU
& Insulin
 5 times less chance of Hypoglycemia than
Glimepiride
 Does not Increase body weight than reduce it
 Convenient Once daily Dose

7. BRANDS…
Brand Name Manufacturer
LINAGLIP Aristopharma
LINITA Square
TRANETA Beximco
LINAROL Drug International
LINATAB Incepta
LIGAZID SK+F
LINAJEN Popular
ADLINA-5 Unimed & Unihealth
GLITIN ACI
LINO 5 Acme

8.  Diabetologists
 Endocrinologists
 Medicine Specialists
 General Practitioners
 RMPs/PCs
TARGET DOCTORS…